Stock Price & Analysis

Based on the current data, AZTA stock is oversold with an RSI of 34.5, suggesting potential exhaustion of selling pressure. It may be a good time to buy for those anticipating a rebound.

Price Prediction for AZTA Stock in 2025

Based on the analysis of technical indicators and analyst sentiment, the price prediction for AZTA stock in 2025 is approximately $43.

The stock is currently trading near its Fibonacci pivot level of $37.83, with resistance levels at $39.76 and $40.96. Analysts have set a price target range of $52 to $60, indicating potential upside.

The stock's RSI of 34.50 suggests it may be undervalued, and recent oversold conditions could signal a rebound.

Analysts are divided, with a Strong Buy, Hold, and Buy ratings, but the average target of $57 supports a bullish outlook.

The stock is expected to reach $43 in the near term, with potential to climb higher if market conditions improve.

The S1 support level for AZTA Stock is $35.9 ,The R1 resistant level for AZTA Stock is $39.76.

As of the end of day on 2025-03-26, the price of AZTA Stock was $35.5.

The target price for AZTA Stock according to analyst rating is 54.20, with the highest price target at 60.00 and the lowest at 50.00. Analysts have a Moderate Buy rating on AZTA Stock overall.

The market cap of AZTA is $1.7B.

Analysis and Insights

Valuation Metrics:

Azenta Inc. (AZTA) currently exhibits high valuation metrics. The EV/EBITDA ratio is approximately 137.94, and the price-to-sales ratio is elevated at 5.44. These metrics suggest that the stock may be overvalued compared to industry peers.

Financial Performance:

The company has shown revenue growth, with Q4 2024 revenue at $170.063 million. However, net income remains negative, indicating profitability challenges. The gross margin is stable, but the net margin is negative, raising concerns about operational efficiency.

Technical Analysis:

The stock's RSI is 29.1, signaling oversold conditions, which may indicate potential exhaustion of selling pressure. The 52-week price range is $38.82 to $67.77, with the current price near the lower end, suggesting possible entry points for bullish investors.

Analyst Sentiment:

Analysts have mixed opinions. While some maintain a "Strong Buy" rating, others have "Hold" or "Sell" recommendations. The lack of consensus adds uncertainty to the stock's outlook.

Conclusion:

AZTA appears overvalued based on its high valuation metrics and negative profitability. However, the oversold technical indicators and lower price range might attract bullish investors. Caution is advised, and it may be prudent to wait for improved financial performance or stabilization before investing.

Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company’s segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

Price Prediction for AZTA Stock by 2030

Based on current trends and analysis, AZTA stock is predicted to reach $55 by 2030. This forecast considers the company's improving revenue, analyst upgrades, and potential growth in the life sciences sector.

AZTA has a total of 3500 employees.